In this study, we determine the risk of contralateral breast cancer in BRCA1, BRCA2, and TP53 PV carriers compared to non-carriers in an extended series of BRCA1/2 and TP53 index cases diagnosed with breast cancer aged 35 years and under. This evidence concerns the gene TP53 and breast carcinoma.